title: Administration of MS-275 improves cognitive performance and reduces cell death following traumatic brain injury in rats.
abstract: OBJECTIVE
  The MS-275 is a selective inhibitor of class I histone deacetylases (HDACs), which has been reported as a potential strategy in some central nervous system diseases associated with neurodegeneration and disturbed learning. However, its role in traumatic brain injury is not well defined. In this study, we examined the behavioral-cognitive performance as well as histology outcome in adult rats to evaluate whether postinjury administration of MS-275 (15 and 45 mg/kg) would provide neuroprotection benefits and ameliorate cognitive deficits following fluid percussion injury.
  
  
  METHODS
  Traumatic brain injury (˜2.15 ATMs) was produced using a fluid percussion device with the lateral orientation. MS-275 was administered (15 and 45 mg/kg) systemically once daily for 7 days starting at 30 min after lateral fluid percussion TBI. Acquisition of spatial learning and memory retention was assessed using the Morris water maze (MWM) on days 10-14 after TBI. Brain tissues were collected and stained with Fluoro-Jade B histofluorescence (for degenerating neurons) at 24 h after injury and cresyl violet (for long-term neuronal survival) on day 14 postinjury.
  
  
  RESULTS
  Behavioral outcome after TBI revealed MS-275 treatment groups, at all doses examined, performed significantly better in the Morris Water Maze (P < 0.001). Acute histology analysis demonstrated that 45 mg/kg MS-275 significantly reduced the number of degenerating neurons in the ipsilateral CA2-3 hippocampus at 24 h postinjury (P = 0.007). There was a trend for MS-275 to increase the survival of neurons in the CA2-3 hippocampus on 14 days after TBI (P = 0.164).
  
  
  CONCLUSIONS
  Our present data highlight the fact that MS-275 may provide neuroprotective effect and improve cognitive performance after TBI. We concluded that MS-275 is a potential novel treatment and will have an ameliorative effect on some of the pathological features associated with TBI.
authors.affiliation: Department of Neurosurgery, Shenyang Northern Hospital, Shenyang, China.
authors.forename: Peng
authors.initials: P
authors.lastname: Cao
authors.forename: Yong
authors.initials: Y
authors.lastname: Liang
authors.forename: Xu
authors.initials: X
authors.lastname: Gao
authors.forename: Ming-Guang
authors.initials: MG
authors.lastname: Zhao
authors.forename: Guo-Biao
authors.initials: GB
authors.lastname: Liang
mesh_terms: D000818:Animals; D001549:Benzamides / Q000494:pharmacology*; D001930:Brain Injuries / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D002470:Cell Survival / Q000187:drug effects; D003071:Cognition / Q000187:drug effects*; D006624:Hippocampus / Q000473:pathology; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology*; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009474:Neurons / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D001549:Benzamides; D056572:Histone Deacetylase Inhibitors; D018696:Neuroprotective Agents; D011725:Pyridines; C118739:entinostat
references.citation: Neuron. 2004 Jun 24;42(6):961-72
references.pmid: 15207240
references.citation: J Neurotrauma. 2001 Nov;18(11):1207-16
references.pmid: 11721739
references.citation: J Neurotrauma. 1994 Jun;11(3):317-24
references.pmid: 7996585
references.citation: Neuropsychopharmacology. 2010 Mar;35(4):870-80
references.pmid: 20010553
references.citation: Acta Neuropathol. 1999 Oct;98(4):396-406
references.pmid: 10502046
references.citation: J Neurotrauma. 2005 Feb;22(2):266-76
references.pmid: 15716632
references.citation: Mol Pharmacol. 2006 Dec;70(6):1876-84
references.pmid: 16946032
references.citation: J Immunol. 2006 Apr 15;176(8):5015-22
references.pmid: 16585598
references.citation: Neuroscience. 1989;28(1):233-44
references.pmid: 2761692
references.citation: Br J Pharmacol. 2007 Apr;150(7):829-31
references.pmid: 17325655
references.citation: Mol Neurobiol. 2009 Aug;40(1):33-45
references.pmid: 19396637
references.citation: Exp Neurol. 2001 May;169(1):191-9
references.pmid: 11312571
references.citation: J Biol Chem. 2002 Jan 18;277(3):2073-80
references.pmid: 11698395
references.citation: Brain Res. 2008 Aug 21;1226:181-91
references.pmid: 18582446
references.citation: Acta Neurochir Suppl. 2004;89:69-74
references.pmid: 15335103
references.citation: Exp Neurol. 2007 Jul;206(1):59-69
references.pmid: 17521631
references.citation: Injury. 2007 Dec;38(12):1392-400
references.pmid: 18048036
references.citation: J Pharmacol Exp Ther. 2007 Jun;321(3):892-901
references.pmid: 17371805
references.citation: Neuroscience. 2004;125(3):803-18
references.pmid: 15099693
references.citation: Toxicol Pathol. 2000 Jan-Feb;28(1):91-9
references.pmid: 10668994
references.citation: Nat Rev Drug Discov. 2008 Oct;7(10):854-68
references.pmid: 18827828
references.citation: Biochem J. 2003 Mar 15;370(Pt 3):737-49
references.pmid: 12429021
references.citation: Nutr Clin Pract. 2008 Dec-2009 Jan;23(6):608-20
references.pmid: 19033220
references.citation: Neurosci Lett. 2008 Aug 15;441(1):115-9
references.pmid: 18583041
references.citation: J Neurosurg. 1987 Jul;67(1):110-9
references.pmid: 3598659
references.citation: Neurochem Res. 2004 Jun;29(6):1275-86
references.pmid: 15176484
references.citation: Br J Pharmacol. 2007 Apr;150(7):862-72
references.pmid: 17325656
references.citation: Glia. 2003 Nov;44(2):140-52
references.pmid: 14515330
references.citation: Acta Neurochir (Wien). 2007;149(9):919-27; discussion 927
references.pmid: 17660938
references.citation: Brain Res. 1997 Mar 14;751(1):37-46
references.pmid: 9098566
references.citation: J Med Chem. 2007 Jun 28;50(13):3054-61
references.pmid: 17539623
references.citation: Nat Rev Neurosci. 2005 Feb;6(2):108-18
references.pmid: 15654323
references.citation: J Neurotrauma. 2004 May;21(5):521-39
references.pmid: 15165361
references.citation: Neurobiol Dis. 2007 May;26(2):464-72
references.pmid: 17398106
references.citation: Neurosurgery. 1998 Oct;43(4):723-37; discussion 737-8
references.pmid: 9766298
references.citation: J Neurotrauma. 2009 Nov;26(11):1911-20
references.pmid: 19929216
references.citation: Brain Res. 2011 Jun 13;1395:62-73
references.pmid: 21565332
references.citation: J Neurosurg. 2001 Oct;95(4):674-9
references.pmid: 11596962
references.citation: Annu Rev Biomed Eng. 2011 Aug 15;13:91-126
references.pmid: 21529164
references.citation: Neuroscience. 2009 Sep 29;163(1):1-8
references.pmid: 19531374
references.citation: J Head Trauma Rehabil. 2006 Sep-Oct;21(5):375-8
references.pmid: 16983222
references.citation: Neuroscience. 2010 Aug 11;169(1):370-7
references.pmid: 20451583
references.citation: Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1587-92
references.pmid: 16432198
references.citation: J Biol Chem. 2005 Jan 7;280(1):556-63
references.pmid: 15494404
references.citation: J Neurosci. 2003 Oct 15;23(28):9418-27
references.pmid: 14561870
references.citation: J Neurotrauma. 2005 Jan;22(1):42-75
references.pmid: 15665602
references.citation: Brain Res. 2006 Mar 10;1077(1):24-36
references.pmid: 16490184
references.citation: Br J Anaesth. 2007 Jul;99(1):4-9
references.pmid: 17573392
references.citation: Brain Res. 2006 Jan 27;1070(1):31-4
references.pmid: 16406269
references.citation: Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
references.pmid: 10200307
references.citation: Curr Pharm Des. 2008;14(6):505-28
references.pmid: 18336297